Physician profile

Wayne Brandes

Family Medicine · Melbourne, FL

NPI 1174962807

$291.02

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$22.42

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $63.38 2021-2022
Amarin Pharma, INC. $61.08 2019-2020
Novo Nordisk INC $36.64 2019-2020
Pfizer INC. $29.75 2019
Astellas Pharma US INC $29.55 2021-2022
Hologic Sales and Service, LLC $22.42 2023 Aptima, Thinprep 2000 Processor
Sanofi-Aventis U.S. LLC $17.77 2020
Nestle Healthcare Nutrition INC. $17.31 2022
Sun Pharmaceutical Industries INC. $13.12 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Wayne Brandes

$291.02

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/1080069/wayne-brandes

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.